ARCHIVES

NCIs FY95 Bypass To Justify $3.47 Billion, includes $490 million For Breast Cancer Research

This article is from The Cancer Letter archive.

Vol. 19 No. 20 | May 14, 1993

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform

May 9, 1997

Community Based Control Program Taking Final Shape

April 29, 1977

Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma

February 22, 2002

In Brief :Three Named to Leadership Posts At St. Jude; Mitchell Weiss Appointed Chair of Hematology

June 11, 2014

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

September 6, 2002